Early growth hormone offers height and nutritional benefits in Silver-Russell syndrome
The first 2 years of recombinant growth hormone therapy offers significant benefits for prepubertal children with Silver–Russell syndrome, French researchers have found.
Plasma and urine testing both ‘reliable’ for paediatric PPGL diagnosis
Plasma and urine analyses are both reliable screening tests for the diagnosis of phaeochromocytoma/paraganglioma in children and adolescents, report researchers in Clinical Endocrinology.
Real-word support for rhIGF-1 treatment in adolescents with severe growth failure
Treatment with recombinant human insulin-like growth factor-1 enables children and adolescents with severe growth failure due to primary IGF-1 deficiency to reach near-adult height, suggest real-world registry data.
AI-assisted tool aids paediatric achondroplasia growth calculations
An artificial intelligence-assisted tool can speed up anthropometric calculations for paediatric endocrinologists monitoring growth in children with achondroplasia, research indicates.
Genetic causes identified for nonfamilial tall stature in childhood
Genetic testing has identified a likely cause for nonfamilial tall stature in 11% of children examined, show study findings published in the European Journal of Pediatrics.
Growth hormone therapy response confirmed for children with heterozygous NPR2 alterations
Research from the Netherlands suggests that the majority of children heterozygous for pathogenic alterations to the NPR2 gene, resulting in mild skeletal dysplasia, respond to growth hormone therapy.
ESPE statement highlights immune checkpoint inhibitor AE knowledge gaps
The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.
Aromatase inhibitor plus rhGH improves adult height for boys with idiopathic short stature
For teenage boys with idiopathic short stature (ISS), combining a third-generation aromatase inhibitor with recombinant human growth hormone therapy can significantly improve adult height, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.
Wide range of 46,XY partial gonadal dysgenesis phenotypes revealed
Study findings demonstrate the broad heterogeneous phenotypes found in children with 46,XY gonadal dysgenesis, with insights into likelihood of spontaneous puberty and risk of gonadal malignancy.
Hormone level thresholds over first year point to congenital hypogonadotropic hypogonadism
Measuring levels of testosterone, inhibin B and anti-Müllerian hormone at different time points over the first year of life may help diagnose congenital hypogonadotropic hypogonadism in infant boys with minor abnormalities of the external genitalia, French researchers say.
